Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12612000025831
Ethics application status
Not yet submitted
Date submitted
4/01/2012
Date registered
6/01/2012
Date last updated
1/03/2012
Type of registration
Prospectively registered
Titles & IDs
Public title
HepaFatTM Scan for the non-invasive measurement of liver fat using magnetic resonance imaging
Query!
Scientific title
For patients with liver disease, is HepaFat Scan as accurate (ie has equal or better sensitivity and specificity) as liver biopsy for measuring liver fat?’
Query!
Secondary ID [1]
279660
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1126-7841
Query!
Trial acronym
NIMFat
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-alcoholic fatty liver disease (NAFLD)
285469
0
Query!
Hepatic steatosis
285470
0
Query!
Condition category
Condition code
Metabolic and Endocrine
285651
285651
0
0
Query!
Other metabolic disorders
Query!
Oral and Gastrointestinal
285652
285652
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
HepaFat Scan is a magnetic resonance (MR) image analysis product to facilitate the non invasive quantification of fat within the liver.
The technology is based on gradient recalled echo imaging using the technique of Dixon et al. However, several novel changes have been made to this established method to enable HepaFat Scan to provide greater degrees of sensitivity and specificity in measuring liver fat than other available methods.
This will be a retrospective study using existing demographic, clinical and MRI image data (obtained between March 2009 and December 2011 and available in institutional databases) from 10 subjects without liver disease (healthy controls) and up to eighty (80) patients with liver disease. Neither patients nor healthy control subjects are required to undergo any additional procedures or MRI scans.
Query!
Intervention code [1]
283941
0
Not applicable
Query!
Comparator / control treatment
Each study participant will have undergone an MRI scan to acquire the image data required for HepaFat Scan as well as a liver biopsy as part of a previous study. The amount of fat that is shown to be present in the liver using the results from HepaFat Scan will be compared to the results of the liver biopsy.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
286204
0
To measure the diagnostic performance of HepaFat Scan to grade liver fat when a histopathologist's visual assessment of liver biopsy specimens is used as the reference standards.
Query!
Assessment method [1]
286204
0
Query!
Timepoint [1]
286204
0
Baseline
Query!
Secondary outcome [1]
295384
0
To measure the diagnostic performance of HepaFat Scan to grade liver fat when a reference standard based on quantitative computer assisted morphometric image analysis of histological sections is used instead of a histopathologist's visual assessment.
Query!
Assessment method [1]
295384
0
Query!
Timepoint [1]
295384
0
Baseline
Query!
Eligibility
Key inclusion criteria
Age 18-65 years
Confirmed diagnosis of liver disease
Liver biopsy within 12 months prior to entry into the study
Alcohol consumption <20 grams/day for men and <10 grams/day for women.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Inability to provide informed consent
Contraindications for MRI
Ischemic heart disease as determined by history or abnormal ECG.
Pregnancy or lactation.
Malignancy (excluding basal cell or squamous cell skin cancers)
Query!
Study design
Purpose
Natural history
Query!
Duration
Cross-sectional
Query!
Selection
Defined population
Query!
Timing
Retrospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/02/2012
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
90
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
284440
0
Commercial sector/Industry
Query!
Name [1]
284440
0
Resonance Health Analysis Services Pty Ltd
Query!
Address [1]
284440
0
PO Box 1135
Nedlands, Western Australia, 6909
Query!
Country [1]
284440
0
Australia
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Resonance Health Analysis Services Limited
Query!
Address
PO Box 1135
Nedlands, Western Australia, 6909
Query!
Country
Australia
Query!
Secondary sponsor category [1]
283363
0
None
Query!
Name [1]
283363
0
Query!
Address [1]
283363
0
Query!
Country [1]
283363
0
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
286418
0
Query!
Ethics committee address [1]
286418
0
Query!
Ethics committee country [1]
286418
0
Query!
Date submitted for ethics approval [1]
286418
0
13/01/2012
Query!
Approval date [1]
286418
0
Query!
Ethics approval number [1]
286418
0
Query!
Summary
Brief summary
This will be a retrospective study using existing demographic, clinical and MRI image data to develop HepaFatTM Scan, a non-invasive tool to quantify liver fat.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
33240
0
Query!
Address
33240
0
Query!
Country
33240
0
Query!
Phone
33240
0
Query!
Fax
33240
0
Query!
Email
33240
0
Query!
Contact person for public queries
Name
16487
0
Helen Pavitt
Query!
Address
16487
0
Resonance Health Analysis Services Pty Ltd
PO Box 1135
Nedlands, Western Australia, 6909
Query!
Country
16487
0
Australia
Query!
Phone
16487
0
+61 8 9286 5300
Query!
Fax
16487
0
+61 8 9286 1179
Query!
Email
16487
0
[email protected]
Query!
Contact person for scientific queries
Name
7415
0
Helen Pavitt
Query!
Address
7415
0
Resonance Health Analysis Services Pty Ltd
PO Box 1135
Nedlands, Western Australia, 6909
Query!
Country
7415
0
Australia
Query!
Phone
7415
0
+61 8 9286 5300
Query!
Fax
7415
0
+61 8 9286 1179
Query!
Email
7415
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF